Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Sacred lotus rhizome (Nelumbo nucifera) is rich in bioactive alkaloids (nuciferine, neferine, liensinine), polysaccharides, and phenolic compounds that inhibit acetylcholinesterase, suppress NF-κB/MAPK inflammatory signaling, and exert potent antioxidant activity via electron transfer and hydrogen atom donation mechanisms (PMID 19298686; PMID 27057194). LC-ESI-QTOF-MS/MS profiling has identified over 20 phenolic compounds in lotus rhizome — including catechin, gallic acid, and chlorogenic acid — that demonstrate significant free-radical scavenging capacity and contribute to its documented anti-inflammatory, antidiabetic, and neuroprotective effects (PMID 35557671; PMID 37635669).
Reported Benefits (Provisional)
Origin & History
Sacred Lotus Rhizome (Nelumbo nucifera) is the underground stem of the Sacred Lotus plant, native to the freshwater lakes and river basins of India, China, and Southeast Asia. Revered across Asian cultures, this aquatic root is a staple in traditional medicine and cuisine. It is valued in functional nutrition for its unique blend of fiber, minerals, and bioactive compounds that support digestive and emotional well-being.
Research Narrative (Provisional)
Mukherjee et al. (2009) published a comprehensive phytochemical and therapeutic profile in the Journal of Pharmacy and Pharmacology, documenting the rhizome's alkaloid, flavonoid, and tannin content alongside anti-inflammatory, antioxidant, and hepatoprotective activities (PMID 19298686). Paudel & Panth (2015) reviewed the biological activity of Nelumbo nucifera in Evidence-Based Complementary and Alternative Medicine, confirming antidiabetic, anti-obesity, and immunomodulatory properties of rhizome extracts in preclinical models (PMID 27057194). Zhu et al. (2022) used LC-ESI-QTOF-MS/MS to characterize phenolic compounds in lotus rhizome, identifying catechin, epicatechin, and chlorogenic acid as primary contributors to antioxidant capacity with DPPH and ABTS radical-scavenging assays (PMID 35557671). De Silva et al. (2023) elucidated molecular mechanisms of antidiabetic action in lotus rhizome, demonstrating that betulinic acid modulates insulin signaling pathways and inhibits α-glucosidase activity in vitro (PMID 37635669).
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Vitamins: Vitamin C, B vitamins (B6, folate) - Minerals: Iron, potassium, zinc, copper - Phytochemicals: Flavonoids (quercetin, kaempferol), tannins, mucilage, polysaccharides - Other: Dietary fiber
Reported Mechanism (Provisional)
The bisbenzylisoquinoline alkaloids neferine and liensinine inhibit acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), while nuciferine acts as a dopamine D2 receptor antagonist and 5-HT2A/2C serotonin receptor modulator, contributing to neuroprotective and anxiolytic effects (PMID 34845950). Rhizome polysaccharides activate macrophage-mediated immunity through toll-like receptor 4 (TLR4) signaling and suppress pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) via inhibition of the NF-κB and MAPK (ERK1/2, JNK, p38) pathways (PMID 36521698; PMID 19298686). Phenolic compounds including gallic acid, catechin, and chlorogenic acid exert antioxidant activity through both single electron transfer (SET) and hydrogen atom transfer (HAT) mechanisms, neutralizing reactive oxygen species and chelating transition metal ions (PMID 35557671). Betulinic acid from lotus rhizome enhances GLUT4 translocation and activates the PI3K/Akt insulin signaling cascade, while inhibiting α-glucosidase and α-amylase enzymes to reduce postprandial glucose (PMID 37635669).
Clinical Narrative (Provisional)
Current evidence consists primarily of in vitro studies demonstrating enzyme inhibition and cellular anti-inflammatory effects. Laboratory studies show 55.75-90.70% inhibition of acetylcholinesterase and 34.72-93.72% inhibition of butyrylcholinesterase at 10 mg/mL concentrations. Macrophage studies confirm significant reduction of inflammatory mediators, but human clinical trials are lacking. The therapeutic potential remains promising but requires randomized controlled trials to establish clinical efficacy and safety.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.